

ESTEVE reinforces its commitment to sustainability in all three dimensions: social, environmental and economic

- **2021 has been a key year for the consolidation of its new business model: to become an international, proprietary and specialized pharmaceutical company.**
- **Some of the milestones that were achieved in 2021 include FDA approval of the first product developed entirely by ESTEVE (Seglentis®), 21% growth in revenues and the approval of a new sustainability strategy.**

Barcelona, May 2022. - ESTEVE announces positive results for fiscal year 2021, testimony to its good strategic performance and its commitment to being a sustainable, responsible company that remains faithful to its pledge to improve people's lives.

Some of the keys to the excellent results obtained in 2021 include the company's development capacity, its rapid response to the needs of its customers and, above all, its commitment to excellence.

Following the recent approval of its new Sustainability Strategy, all decision-making processes are now based on environmental, social and corporate governance criteria. Caring for people, caring for the environment and caring for the business are the three pillars that underpin this strategy, in line with the United Nations Sustainable Development Goals for 2030.

Caring for people

More than 1,500 people worldwide, representing 22 different nationalities, are the driving force behind ESTEVE's results. That is why the company strives to foster the individual growth of its team members, professional development based on equality and diversity, and a culture based on transparency, accountability and the importance of people.

As part of this same pillar, in 2021 the company allocated more than 800,000 euros to social programs and collaborations with civil and healthcare organizations.

Furthermore, its commitment to patient-focused innovation is evidenced by the US Food and Drug Administration's (FDA) approval of Seglentis®, a cocrystalline form of celecoxib (an anti-inflammatory drug) and tramadol (an analgesic) for the treatment of acute pain in adults. ¹⁻³

Caring for the environment

The company's commitment to reduce CO₂ emissions can be seen in both its Voluntary Agreements Programme and the fact that it has joined the Ministry for the Ecological Transition's Carbon Footprint Register. Because mitigating climate change is one of the company's priorities: ESTEVE supports initiatives designed to reduce greenhouse gas emissions. In terms of energy management, the company's 100% use of renewable energies in all its production plants in Spain, the installation of solar panels for energy self-consumption in its sites, and the promotion of sustainable mobility plans should be highlighted.

Good resource management is also another priority: the company reduced its water consumption by 3% in 2021.

Caring for the business

ESTEVE closed 2021 with 550 million euros in net revenues, 21% more than in 2020. Of this amount, 67% came from the international market. More than 60% of the company's income comes from proprietary products, in line with its strategy. Equally important is its entry into the hospital market with specialized drugs, a segment that already accounts for more than 20% of pharmaceutical sales.

2021 was also the year in which the company successfully completed its internationalization with the integration of its pharmaceutical subsidiaries in Germany, France and the United Kingdom, as well as its entry into the Portuguese market.

For further information: [2021 Annual Report](#)

About ESTEVE

ESTEVE (www.esteve.com) is a global pharmaceutical company with headquarters in Barcelona. Its mission is to advance in innovation to improve people's lives and, since it was founded in 1929, its focus has been to provide solutions for as yet unmet medical needs. ESTEVE has an important presence in Europe thanks to its affiliates in Spain, Portugal, Germany, France and UK and its own production centers dedicated to the development and manufacture of active pharmaceutical ingredients in Spain, Mexico and China, as well as a pharmaceutical plant in Germany.

References

1. Expert Opinion on Investigational Drugs. 2019;28(5):399-409.
2. Journal of Pain Research. 2019;12:2679-2689.
3. Crystal Growth & Design. 2017;17(4):1884-1892 and 2019;19(6):3172-3182.